## Edgar Filing: IMMUNOGEN INC - Form 4

IMMUNOC Form 4	SEN INC								
July 14, 201	5								
•						OMB A	PPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							3235-0287 January 31,		
Check th if no lon subject th Section Form 4 of Form 5 obligation may cont <i>See</i> Instat 1(b).	section 17(	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940							
(Print or Type	Responses)								
1. Name and Address of Reporting Person <u>*</u> Harrison Ellie			2. Issuer Name <b>an</b> mbol MMUNOGEN	d Ticker or Trading INC [IMGN]	5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (I	Middle) 3.	Date of Earliest T	ransaction	(Check all applicable)				
C/O IMMUNOGEN, INC., 830 WINTER STREET			10nth/Day/Year) 7/13/2015		Director 10% Owner X Officer (give title Other (specify below) below) VP & Chief HR Officer				
	(Street)		If Amendment, D led(Month/Day/Yea	-	<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
WALTHA	M, MA 02451				Person	lore than One R	eporting		
(City)	(State)	(Zip)	Table I - Non-l	Derivative Securities A	cquired, Disposed of	, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Dat any	Code Year) (Instr. 8)	4. Securities nAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Price	SecuritiesFBeneficially(IOwned(I	. Ownership orm: Direct D) or Indirect ) instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder De	port on a concrete line	for each alace			or indirectly				
Kenninder: Ke	port on a separate line		or securities bene.	information cont required to resp	spond to the collect ained in this form a ond unless the form ntly valid OMB con	are not n	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount o
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: IMMUNOGEN INC - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Yea	r) (Instr. )	8)	Acquired or Dispos (D) (Instr. 3, 4 and 5)	ed of				
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock option (right to buy)	\$ 16.72	07/13/2015	А		70,000		07/13/2016 <u>(1)</u>	07/13/2025	Common stock	70,000

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Harrison Ellie C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM, MA 02451			VP & Chief HR Officer				
Signatures							
/s/ Craig Barrows, attorney in fact	(	07/14/2015					

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercisable as to 23,334 shares commencing on July 13, 2016, 23,333 shares commencing on July 13, 2017 and 23,333 shares commencing on July 13, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.